Associate Professor

Colm Keane

Email: 
Phone: 
+61 7 344 37912

Background

Dr Keane is a haematologist at Princess Alexandra Hospital and runs the Lymphoma Research Lab at the UQDI in Brisbane. His main research interest is focused on the interface between the tumour microenvironment and the malignant lymphoma cell, with a goal to build an understanding of lymphoma from an immunological and biomarkers perspective. To bridge developments between the clinic and bench-top, the laboratory has a strong emphasis on patient material, which it obtains from international and national clinical collaborators, much being from investigator-led clinical trials.

Lymphomas studied include more common lymphomas such as Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma and Follicular Lymphoma but his lab has a particular focus on rare lymphomas such as primary central nervous system lymphoma and lymphomas that develop in patients who are immunocompromised.

Dr. Keane has been instrumental in translating work from his lab into multiple immune based clinical trials currently being run across Australia, many in rare and hard to treat lymphomas, where patients have limited treatments available.

The goals of the lab are to directly improve outcomes for all lymphoma patients by performing innovative translational science that not only generates new knowledge and brings new treatments to Australian patients but helps to train the next generation of lymphoma researchers in Australia.

Availability

Associate Professor Colm Keane is:
Available for supervision

Qualifications

  • Masters (Coursework) of Business Administration, Griffith University
  • Doctor of Philosophy, Griffith University

Research interests

  • Tumour Immunology

  • DLBCL

  • Primary CNS Lymphoma

  • Hodgkin Lymphoma

  • Viral Associated Lymphomas

Search Professor Colm Keane’s works on UQ eSpace

143 works between 2004 and 2025
All (143) Journal Article (80) Conference Publication (62) Book Chapter (1)

101 - 120 of 143 works

2017

Journal Article

Stem cell-based therapies for sepsis

Keane, Colm, Jerkic, Mirjana and Laffey, John G. (2017). Stem cell-based therapies for sepsis. Anesthesiology, 127 (6), 1017-1034. doi: 10.1097/ALN.0000000000001882

Stem cell-based therapies for sepsis

2017

Journal Article

The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B-cell lymphoma

Keane, Colm, Gould, Clare, Jones, Kimberley, Hamm, David, Talaulikar, Dipti, Ellis, Jonathan, Vari, Frank, Birch, Simone, Han, Erica, Wood, Peter, Le-Cao, Kim-Anh, Green, Michael R., Crooks, Pauline, Jain, Sanjiv, Tobin, Josh, Steptoe, Raymond J. and Gandhi, Maher K. (2017). The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B-cell lymphoma. Clinical Cancer Research, 23 (7), 1820-1828. doi: 10.1158/1078-0432.CCR-16-1576

The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B-cell lymphoma

2017

Conference Publication

The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia

Tobin, Joshua W. D., Royle, Jane, Mason, Robert, Michael, Millward, Lydia, Warburton, Sandhu, Shahneen, Haydon, Andrew, Long, Georgina, Carlino, Matteo, Smith, Jessica L., Dearden, Helen, Mollee, Peter, Gill, Devinder, Mapp, Sally, Atkinson, Victoria and Keane, Colm (2017). The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology.

The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia

2017

Conference Publication

The impact of EBV upon the tumor microenvironment and mutational profile of primary CNS lymphoma in PTLD

Gandhi, Maher K., Keane, Colm, Tobin, Joshua W. D., Talaulikar, Dipti, Jain, Sanjiv, Vari, Frank, Kruze, Lutz, Murigneux, Valentine, Fink, Lynn, Gunawardana, Jithendra, Gould, Clare, Oey, Harold, Fink, Susanne, Trappe, Ralf Ulrich, Mathews, Marina, Francis, Santiyagu and Hoang, Thanh (2017). The impact of EBV upon the tumor microenvironment and mutational profile of primary CNS lymphoma in PTLD. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA, United States, 9-12 December 2017. Washington, DC, United States: American Society of Hematology.

The impact of EBV upon the tumor microenvironment and mutational profile of primary CNS lymphoma in PTLD

2017

Conference Publication

The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial

Shanavas, Mohamed, Hertzberg, Mark, Hicks, Rodney J., Seymour, John F., Tobin, Joshua W. D., Mathews, Marina, Francis, Santiyagu, Vari, Frank, Gandhi, Maher K. and Keane, Colm (2017). The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology.

The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial

2016

Journal Article

The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma

Jones, K., Wockner, L., Brennan, R. M., Keane, C., Chattopadhyay, P. K., Roederer, M., Price, D. A., Cole, D. K., Hassan, B., Beck, K., Gottlieb, D., Ritchie, D. S., Seymour, J. F., Vari, F., Crooks, P., Burrows, S. R. and Gandhi, M. K. (2016). The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma. Clinical and Experimental Immunology, 183 (2), 206-220. doi: 10.1111/cei.12716

The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma

2016

Conference Publication

A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma

Gandhi, Maher K., Arpon, David, Keane, Colm, Han, Erica, Tobin, Josh, Bird, Robert, Hertzberg, Mark S., Self, Marlene, Cross, Donna, Hernandez, Annette and Vari, Frank (2016). A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma. 58th Annual Meeting and Exposition of the American-Society-of-Hematology, San Diego CA, United States, 3-6 December 2016. Washington, DC United States: American Society of Hematology.

A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma

2015

Journal Article

Copy-number variation and false positive results of prenatal screening

Kingsley, Christopher, Wang, Eric, Oliphant, Arnold, Van Den Boom, Dirk, Ehrich, Mathias, Kim, Sung K., Jivan, Yatika, Peach, Betsy, Keane, Colm, Snyder, Matthew W., Gammill, Hilary S. and Shendure, Jay (2015). Copy-number variation and false positive results of prenatal screening. New England Journal of Medicine, 373 (26), 2583-2585. doi: 10.1056/NEJMc1507106

Copy-number variation and false positive results of prenatal screening

2015

Journal Article

Copy-number variation and false positive results of prenatal screening

Jivan, Yatika, Peach, Betsy and Keane, Colm (2015). Copy-number variation and false positive results of prenatal screening. The New England Journal of Medicine, 373 (26), 2584-2585. doi: 10.1056/NEJMc1507106

Copy-number variation and false positive results of prenatal screening

2015

Journal Article

Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study

Keane, Colm, Vari, Frank, Hertzberg, Mark, Le Cao, Kim-Anh, Green, Michael R., Han, Erica, Seymour, John F., Hicks, Rodney J., Gill, Devinder, Crooks, Pauline, Gould, Clare, Jones, Kimberley, Griffiths, Lyn R., Talaulikar, Dipti, Jain, Sanjiv, Tobin, Josh and Gandhi, Maher K. (2015). Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematology, 2 (10), e445-e455. doi: 10.1016/S2352-3026(15)00150-7

Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study

2015

Journal Article

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing

Kurtz, David M., Green, Michael R., Bratman, Scott V., Scherer, Florian, Liu, Chih Long, Kunder, Christian A., Takahashi, Kazuhiro, Glover, Cynthia, Keane, Colm, Kihira, Shingo, Visser, Brendan, Callahan, Jason, Kong, Katherine A., Faham, Malek, Corbelli, Karen S., Miklos, David, Advani, Ranjana H., Levy, Ronald, Hicks, Rodney J., Hertzberg, Mark, Ohgami, Robert S., Gandhi, Maher K., Diehn, Maximilian and Alizadeh, Ash A. (2015). Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 125 (24), 3679-3687. doi: 10.1182/blood-2015-03-635169

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing

2015

Journal Article

Prehospital use of magnesium sulfate as neuroprotection in acute stroke

Saver, Jeffrey L., Starkman, Sidney, Eckstein, Marc, Stratton, Samuel J., Pratt, Franklin D., Hamilton, Scott, Conwit, Robin, Liebeskind, David S., Sung, Gene, Kramer, Ian, Moreau, Gary, Goldweber, Robert, Sanossian, Nerses, Ali, A., Andruss, K., Beck, B., Chin, S., Conneen, D., Copeland, D., Crisan, A., Gale, L., Ganguly, G., Gonzalez, J. E., Helfgott, P., Hovanessian, H., Jarema, E., Liu, M., Martin, M. L., Meyer, G. ... Sacco, R. (2015). Prehospital use of magnesium sulfate as neuroprotection in acute stroke. New England Journal of Medicine, 372 (6), 528-536. doi: 10.1056/NEJMoa1408827

Prehospital use of magnesium sulfate as neuroprotection in acute stroke

2015

Conference Publication

Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios

Lecao K.-A., Keane C., Han E., Talaulikar D. and Gandhi M. (2015). Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios. Scientific Stream at Big Data in Health Analytics 2015, BigData 2015, Sydney; Australia, October 20, 2015-October 21, 2015. Aachen, Germany: Rheinisch-Westfaelische Technische Hochschule Aachen.

Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios

2015

Conference Publication

Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL)

Scherer, Florian, Kurtz, David Matthew, Green, Michael Richard, Newman, Aaron M., Klass, Daniel M., Zhou, Li, Krishnan, Rashi, Liu, Chih Long, Glover, Cynthia, Ohgami, Robert S., Hicks, Rodney J., Keane, Colm, Kong, Katherine A., Faham, Malek, Hertzberg, Mark S., Gandhi, Maher K., Advani, Ranjana H., Levy, Ronald, Diehn, Maximilian and Alizadeh, Ash A. (2015). Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL). Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, United States, May 29-June 2, 2015. Alexandria, United States: American Society of Clinical Oncology.

Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL)

2015

Conference Publication

The T Cell Receptor (TCR) Repertoire Is a Key Determinant of the Tumour Microenvironment (TME) in Diffuse Large B Cell Lymphoma (DLBCL)

Keane, Colm, Jones, Kimberly, Gould, Clare, Hamm, David, Wood, Peter, Birch, Simone, Crooks, Pauline, Green, Michael R., Taulaulikar, Dipti, Jain, Sanjiv, Tobin, Josh and Gandhi, Maher K. (2015). The T Cell Receptor (TCR) Repertoire Is a Key Determinant of the Tumour Microenvironment (TME) in Diffuse Large B Cell Lymphoma (DLBCL). 55th Annual Meeting and Exposition of the American-Society-of-Hematology, New Orleans, LA, United States, 7-10 December 2013. WASHINGTON: AMER SOC HEMATOLOGY.

The T Cell Receptor (TCR) Repertoire Is a Key Determinant of the Tumour Microenvironment (TME) in Diffuse Large B Cell Lymphoma (DLBCL)

2014

Journal Article

A comprehensive analysis of the cellular and EBV-Specific MicroRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors

Fink, S. E. K., Gandhi, M. K., Nourse, J. P., Keane, C., Jones, K., Crooks, P., Johrens, K., Korfel, A., Schmidt, H., Neumann, S., Tiede, A., Jager, U., Duhrsen, U., Neuhaus, R., Dreyling, M., Borchert, K., Sudhoff, T., Riess, H., Anagnostopoulos, I. and Trappe, R. U. (2014). A comprehensive analysis of the cellular and EBV-Specific MicroRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors. American Journal of Transplantation, 14 (11), 2577-2587. doi: 10.1111/ajt.12858

A comprehensive analysis of the cellular and EBV-Specific MicroRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors

2014

Conference Publication

Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL

Kurtz, David Matthew, Green, Michael R., Bratman, Scott Victor, Liu, Chih-Long, Glover, Cynthia, Keane, Colm, Kong, Katie, Faham, Malek, Miklos, David Bernard, Advani, Ranjana H., Levy, Ronald, Hertzberg, Mark S., Gandhi, Maher K., Diehn, Maximilian and Alizadeh, Ash A. (2014). Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. 50th Annual Meeting of the American Society of Clinical Oncology, Chicago IL United States, May 30-June 3, 2014. Alexandria VA, United States: American Society of Clinical Oncology.

Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL

2014

Journal Article

Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma

Jones, Kimberley, Nourse, Jamie P., Keane, Colm, Bhatnagar, Atul and Gandhi, Maher K. (2014). Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. Clinical Cancer Research, 20 (1), 253-264. doi: 10.1158/1078-0432.CCR-13-1024

Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma

2013

Journal Article

CD4+Tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy

Keane, Colm, Gill, Devinder, Vari, Frank, Cross, Donna, Griffiths, Lynn and Gandhi, Maher (2013). CD4+Tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. American Journal of Hematology, 88 (4), 273-276. doi: 10.1002/ajh.23398

CD4+Tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy

2013

Journal Article

Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma

Jones, Kimberley, Vari, Frank, Keane, Colm, Crooks, Pauline, Nourse, Jamie P., Seymour, Louise A., Gottlieb, David, Ritchie, David, Gill, Devinder and Gandhi, Maher K. (2013). Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clinical Cancer Research, 19 (3), 731-742. doi: 10.1158/1078-0432.CCR-12-2693

Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma

Current funding

  • 2024 - 2029
    BrainCAR19 Study- Treatment of relapsed Primary Brain Lymphoma with CD19 directed CAR-T cells
    NHMRC MRFF CTA - Clinical Trials Activity
    Open grant
  • 2022 - 2027
    An early phase, open label, multi-centre trial of front-line TheRapy for EBv-associated Lymphomas -- 2: TREBL-2 (Stream 6)
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2021 - 2026
    ALLGNHL32 Study - An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma
    Australasian Leukaemia & Lymphoma Group
    Open grant
  • 2021 - 2026
    Investigation of Immune evasion in relapsed lymphoma (RADD Trial) (Victorian Cancer Agency Translational Research Project administered by La Trobe University)
    Olivia Newton-John Cancer Research Institute
    Open grant
  • 2021 - 2026
    Immuno-genetic biomarkers of response in a prospective study of immune checkpoint therapy in primary CNS lymphoma
    NHMRC MRFF Investigator Grant
    Open grant
  • 2019 - 2026
    An Open Label, Multicentre, Phase One Study Incorporating Early Application of CAR T cells for Primary Refractory Aggressive Lymphoma
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant

Past funding

  • 2021 - 2025
    Employing rational novel agent combination therapy to improve transplant cure rates for relapsed/refractory Hodgkin Lymphoma (MRFF RCRDUN administered by La Trobe University)
    La Trobe University
    Open grant
  • 2020 - 2023
    Novel immune based approaches to improve survival for patients with Primary Central Nervous Lymphoma
    Queensland Advancing Clinical Research Fellowship
    Open grant
  • 2019 - 2020
    Investigation of the key immuno-genetic drivers of Primary Central Nervous System Lymphoma that occurs in patients with HIV infection
    Cancer Australia
    Open grant
  • 2018 - 2025
    An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies
    NHMRC MRFF - Lifting Clinical Trials Registries Capacity
    Open grant
  • 2017 - 2020
    Investigation of unique immune microenvironment of Primary CNS Lymphoma
    NHMRC Early Career Fellowships
    Open grant
  • 2017 - 2019
    The prognostic utility of the tumour microenvironment in Non-Hodgkin's Lymphoma
    Celgene Pty Ltd
    Open grant
  • 2016 - 2017
    Does lymphoma avoid immune destruction by inducing T-cell tolerance?
    Cancer Council Queensland
    Open grant
  • 2015 - 2018
    A correlative laboratory study of primary CNS lymphoma
    Research Donation Generic
    Open grant
  • 2015 - 2018
    Net tumoral immunity and its impact on outcome in lymphoma
    The Leukaemia Foundation of Australia Limited
    Open grant

Availability

Associate Professor Colm Keane is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Supervision history

Current supervision

Completed supervision

Enquiries

For media enquiries about Associate Professor Colm Keane's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au